GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Newbury Pharmaceuticals AB (OSTO:NEWBRY) » Definitions » LT-Debt-to-Total-Asset

Newbury Pharmaceuticals AB (OSTO:NEWBRY) LT-Debt-to-Total-Asset : 0.00 (As of May. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Newbury Pharmaceuticals AB LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Newbury Pharmaceuticals AB's long-term debt to total assests ratio for the quarter that ended in May. 2025 was 0.00.

Newbury Pharmaceuticals AB's long-term debt to total assets ratio stayed the same from May. 2024 (0.00) to May. 2025 (0.00).


Newbury Pharmaceuticals AB LT-Debt-to-Total-Asset Historical Data

The historical data trend for Newbury Pharmaceuticals AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Newbury Pharmaceuticals AB LT-Debt-to-Total-Asset Chart

Newbury Pharmaceuticals AB Annual Data
Trend Aug21 Aug22 Aug23 Aug24
LT-Debt-to-Total-Asset
- - - -

Newbury Pharmaceuticals AB Quarterly Data
Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Newbury Pharmaceuticals AB LT-Debt-to-Total-Asset Calculation

Newbury Pharmaceuticals AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Aug. 2024 is calculated as

LT Debt to Total Assets (A: Aug. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Aug. 2024 )/Total Assets (A: Aug. 2024 )
=0/90.871
=0.00

Newbury Pharmaceuticals AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in May. 2025 is calculated as

LT Debt to Total Assets (Q: May. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: May. 2025 )/Total Assets (Q: May. 2025 )
=0/92.854
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Newbury Pharmaceuticals AB  (OSTO:NEWBRY) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Newbury Pharmaceuticals AB LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Newbury Pharmaceuticals AB's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Newbury Pharmaceuticals AB Business Description

Traded in Other Exchanges
N/A
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.

Newbury Pharmaceuticals AB Headlines

No Headlines